Re: Overall Survival of Men with Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy

被引：0

作者：

Sweeney, C. J.

Martin, A. J.

Stockler, M. R.

Begbie, S.

Chi, K. N.

Chowdhury, S.

Coskinas, X.

Frydenberg, M.

Hague, W. E.

Horvath, L. G.

Joshua, A. M.

Lawrence, N. J.

Marx, G. M.

McCaffrey, J.

McDermott, R.

McJannett, M.

North, S. A.

Parnis, F.

Parulekar, W.

Pook, D. W.

Reaume, M. N.

Sandhu, S. K.

Tan, A.

Tan, T. H.

Thomson, A.

Tu, E.

Vera-Badillo, F.

Williams, S. G.

Yip, S.

Zhang, A. Y.

Zielinski, R. R.

Davis, I. D.

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Harvard Med Sch, Boston, MA 02115 USA

[3] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia

[4] Concord Repatriat Gen Hosp, Concord Canc Ctr, Concord, Australia

[5] Chris Obrien Lifehouse RPA, Sydney, NSW, Australia

[6] Port Macquarie Base Hosp, Port Macquarie, NSW, Australia

[7] Mid North Coast Canc Inst Port Macquarie, Port Macquarie, NSW, Australia

[8] BC Canc Agcy, Vancouver, BC, Canada

[9] Univ British Columbia, Vancouver, BC, Canada

[10] CRUK & Kings Coll London, Guys & St Thomas NHS Fdn Trust Biomed Res Ctr, London, England

[11] Sarah Cannon Res UK, London, England

[12] Monash Univ, Melbourne, Vic, Australia

[13] Australian Urol Associates, Melbourne, Vic, Australia

[14] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia

[15] Garvan Inst Med Res, Sydney, NSW, Australia

[16] Auckland City Hosp, Auckland, New Zealand

[17] Sydney Adventist Hosp, Wahroonga, Australia

[18] Canc Trials Ireland, Dublin, Ireland

[19] Mater Misericordiae Univ Hosp, Dublin, Ireland

[20] St Vincents Univ Hosp, Dublin, Ireland

[21] Univ Coll Dublin, Dublin, Ireland

[22] ANZUP Canc Trials Grp, Camperdown, NSW, Australia

[23] Cross Canc Inst, Edmonton, AB, Canada

[24] Univ Alberta, Edmonton, AB, Canada

[25] Adelaide Canc Ctr, Adelaide, SA, Australia

[26] Univ Adelaide, Adelaide, SA, Australia

[27] Queens Univ, Canadian Canc Trials Grp CCTG, Kingston, ON, Canada

[28] Monash Hlth, Melbourne, Vic, Australia

[29] Univ Ottawa, Ottawa, ON, Canada

[30] Ottawa Hosp Res Inst, Ottawa, ON, Canada

[31] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[32] Univ Melbourne, Melbourne, Vic, Australia

[33] Waikato Dist Hlth Board, Hamilton, New Zealand

[34] Royal Adelaide Hosp, Adelaide, SA, Australia

[35] Royal Cornwall Hosp, Truro, Cornwall, England

[36] Kingston Hlth Sci Ctr, Kingston, ON, Canada

[37] Macquarie Univ, Sydney, NSW, Australia

[38] Orange Hlth Serv, Cent West Canc Care Ctr, Orange, Australia

[39] Univ Western Sydney, Sydney, NSW, Australia

[40] Eastern Hlth, Melbourne, Vic, Australia

来源：

JOURNAL OF UROLOGY | 2021年 / 206卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1519 / 1520

页数：3

共 50 条

[1] Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
Sweeney, Christopher J.
Martin, Andrew J.
Stockler, Martin R.
Begbie, Stephen
Chi, Kim N.
Chowdhury, Simon
Coskinas, Xanthi
Frydenberg, Mark
Hague, Wendy E.
Horvath, Lisa G.
Joshua, Anthony M.
Lawrence, Nicola J.
Marx, Gavin M.
McCaffrey, John
McDermott, Ray
McJannett, Margaret
North, Scott A.
Parnis, Francis
Parulekar, Wendy
Pook, David W.
Reaume, M. Neil
Sandhu, Shahneen K.
Tan, Alvin
Tan, Thean Hsiang
Thomson, Alastair
Tu, Emily
Vera-Badillo, Francisco
Williams, Scott G.
Yip, Sonia
Zhang, Alison Y.
Zielinski, Robert R.
Davis, Ian D.
EUROPEAN UROLOGY, 2021, 80 (03) : 275 - 279
[2] Androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer: ARCHES
von Bueren, Moritz
Armstrong, Andrew J.
Szmulewitz, Russell
Petrylak, Daniel
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Sugg, Jennifer
Baron, Benoit
Chen, Lucy
Stenzl, Arnulf
SWISS MEDICAL WEEKLY, 2019, 149 : 16S - 16S
[3] ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Armstrong, Andrew J.
Szmulewitz, Russell Z.
Petrylak, Daniel P.
Holzbeierlein, Jeffrey
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Sugg, Jennifer
Baron, Benoit
Chen, Lucy
Stenzl, Arnulf
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) : 2974 - +
[4] Quantifying Clinical Utility of Enzalutamide for Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
Sun, Ryan
Wei, Lee-Jen
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36) : 4278 - +
[5] Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study
Iguchi, Taro
Kimura, Go
Fukasawa, Satoshi
Suzuki, Hiroyoshi
Uemura, Hiroji
Nishimura, Kazuo
Matsumoto, Hiroaki
Yokomizo, Akira
Armstrong, Andrew J.
Rosbrook, Brad
Sugg, Jennifer
Baron, Benoit
Chen, Lucy
Kunieda, Futoshi
Stenzl, Arnulf
INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (07) : 765 - 773
[6] Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II Trial
Burgess, Earle F.
Grigg, Claud M.
Boselli, Danielle
Symanowski, James T.
Golshayan, Alireza
Graham, David L.
Osei-Boateng, Kwabena
Gavini, Nagajyothi
Zhu, Jiang
Brown, Landon C.
Norek, Sarah
Begic, Xhevahire J.
Raghavan, Derek
CLINICAL GENITOURINARY CANCER, 2025, 23 (02)
[7] Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial
Stenzl, A.
Krivoshik, A.
Baron, B.
Hirmand, M.
Armstrong, A.
ANNALS OF ONCOLOGY, 2016, 27
[8] The Overall Survival and Safety of Men with Metastatic Hormone-Sensitive Prostate Cancer Treated with Combination Therapy of Novel Androgen Receptor Antagonists and Androgen-Deprivation Therapy: A Systematic Review and Meta-Analysis
Wu, Xupeng
Han, Haisong
Zhang, Chao
Song, Wei
JOURNAL OF ONCOLOGY, 2022, 2022
[9] Phase 3 Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Metastatic Hormone-Sensitive Prostate Cancer: the ARCHES Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 10 - 12
[10] Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer A Randomized Clinical Trial
Vaishampayan, Ulka N.
Heilbrun, Lance K.
Monk, Paul, III
Tejwani, Sheela
Sonpavde, Guru
Hwang, Clara
Smith, Daryn
Jasti, Pallavi
Dobson, Kimberlee
Dickow, Brenda
Heath, Elisabeth I.
Semaan, Louie
Cher, Michael L.
Fontana, Joseph A.
Chinni, Sreenivasa
JAMA NETWORK OPEN, 2021, 4 (01) : E2034633

← 1 2 3 4 5 →